Council of the European Union

Brussels, 16 May 2025
(OR. en)

8487/25

Interinstitutional Files:
2023/0131 (COD)
2023/0132 (COD)

LIMITE

SAN 186
PHARM 56
MI 264
COMPET 312
VETER 50
ENV 292
RECH 183
CODEC 522
PI 74
IA 36
UK 60

PUBLIC

NOTE

From:	General Secretariat of the Council
To:	Permanent Representatives Committee
Subject:	Pharmaceutical package a) Directive on the Union code relating to medicinal product for human use b) Regulation laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency *- Mandate for negotiations with the European Parliament*

I. INTRODUCTION

1. On 26 April 2023 the Commission adopted a proposal for the revision of the pharmaceutical legislation, consisting of a Directive on the Union code relating to medicinal products for human use[1] and a Regulation on Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency[2]. The ordinary legislative procedure is applicable. The proposals were accompanied by an impact assessment on which an exchange of views was held under the Spanish

[1] 8759/23
[2] 8758/23

Presidency. The two legislative proposals aim to adapt and simplify the current regulatory landscape, which consists of one Directive and three Regulations covering both general legislation and specific legislation on medicines for rare diseases and for children.

2. The general objectives of the two legislative proposals are ensuring the quality, safety and efficacy of medicines for EU patients and harmonising the internal market. They specifically aim to promote innovation and ensure access to innovative and affordable medicines; improve security of supply of medicines and address shortages; support innovation and competitiveness through reduced regulatory burden and through a simplified and flexible regulatory framework; and reduce the environmental impact of the pharmaceutical lifecycle.

3. On 24 October 2023, the Committee of the Regions (CoR) sent a renunciation letter regarding the consultation on the Regulation due to the little regional or local relevance of this proposal[3]. On 25 October 2023, the European Economic and Social Committee (EESC) adopted its opinion on the proposals [4].

4. The Senate of the Parliament of the Czech Republic submitted a resolution on both the Regulation and the Directive, raising concerns on certain aspects of the package. The Romanian Senate submitted an opinion raising proportionality concerns and making several recommendations. The German Bundesrat supported the structure of the proposals, but also raised concerns on certain aspects. The Italian Chamber of Deputies and the Italian Senate submitted generally positive assessments on the proposals, while also expressing concerns on certain aspects of the proposal.

[3] 15273/23
[4] 14863/23

5. At the European Parliament, when the proposals were put forward by the Commission, the Committee on the Environment, Public Health and Food Safety (ENVI) was designated as responsible committee. The ENVI Committee adopted its report on both the legislative proposals on 19 March 2024, which was voted in plenary session on 10 April 2024. The responsibility for both legislative proposals transferred to the newly established Committee on Public Health (SANT) in 2025. The rapporteurs are Tiemo Wölken (S&D, Germany) for the Regulation and Dolors Montserrat (EPP, Spain) for the Directive.

II. STATE OF PLAY

6. The Swedish Presidency organised one meeting of the Working Party (WP) on Pharmaceuticals and Medical Devices, dedicated to the presentation by the Commission of the pharmaceutical package. The Spanish Presidency organised two WP meetings, dedicated to the examination of the impact assessment, to the presentation of the opinion of the EESC and a subsequent exchange of views. The Belgian Presidency organised fifteen WP meetings, mainly focusing on the 'shortages', 'authorisations' and 'incentives' clusters, including discussions on several revised texts. In addition, Coreper discussed a state of play on the 'shortages cluster' on 29 May 2024[5], and a policy debate took place on the 'incentives cluster' at the EPSCO (Health) Council of 21 June 2024[6]. The Hungarian Presidency also organised fifteen WP meetings, mainly focusing on the 'incentives cluster', but also including in-depth discussions on the clusters related to 'authorisations', 'subject matter and scope', 'governance of the European Medicines Agency', 'orphans and paediatrics' and 'shortages'. Several revised texts were put forward to the WP, a progress report was presented at the EPSCO (Health) Council of 3 December 2024[7], and Coreper held an exchange of views on the state of play[8] of the file on 18 December 2024.

---

5 9840/1/24 REV 1.
6 9557/24.
7 14955/24.
8 16051/24.

7. The Polish Presidency organised thirteen WP meetings, opening the remaining parts of the proposals, i.e. the clusters related to 'manufacturing and import', 'pharmacovigilance', 'homeopathics and herbals', 'final provisions and Brexit', 'labelling, advertising and prescriptions' and discussing all previously opened parts of the proposals, as listed in paragraph 6, with the aim to obtain a mandate for negotiations with the European Parliament.

8. Based on the examination of the proposals by the Commission, on written comments from delegations and building on discussions in the WP, intermediate revised texts, the guidance provided by Coreper and the EPSCO (Health) Council, the Presidency put forward full compromise texts, which were examined at the WP meetings of 5, 6 and 12 May 2025.

9. Key issues addressed throughout the entire examination of the package were: the proposed modulation of regulatory protection periods for innovative medicines, which the current text aims to simplify with a view to obtain predictability for manufacturers and patients; the introduction of an obligation to supply the markets of the EU and the establishment of Union penalties in case of non-compliance; the risk of an excessive budgetary impact of the use of the transferable exclusivity voucher; the scope of the exemption to the protection of intellectual property rights (the Bolar exemption); the empowerment of the Commission in the case of shortages of medicinal products; the possibility for Member States to implement the information system concerning the distribution of medicinal products from one market to another; introducing the electronic leaflet in parallel to the paper version, unless the Member State decides to require only the electronic version for some or all medicinal products; ensuring that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) can draw on the appropriate expertise for its opinions; representation of and voting rights for patients and healthcare professionals in the CHMP and the Pharmacovigilance Risk Assessment Committee; technical adaptations in some the pharmacovigilance provisions; clarification of the provisions related to decentralised manufacturing; modification of the provisions on joint inspections; clarification of the exemptions related to officinal formula and magistral formula; framing of the scope of adapted frameworks and regulatory sandboxes; and adjustment of various procedural timelines.

PUBLIC

10. Following the last WP meetings on 5, 6 and 12 May 2025, delegations were informed that Coreper would be invited to examine the texts with a view to reach an agreement and to mandate the Presidency to enter into negotiations with the European Parliament. Taking into account the comments made during these last WP meetings, as well as subsequent written comments, further changes in the texts were implemented to address outstanding issues, in particular:
    - in the proposed Directive, related to the scope (Art. 3), prescription of antimicrobials (Art. 51), parallel trade (Art. 162, para 3a), the inclusion of a new provision on the assessment of borderline cases (Art. 201a), the inclusion of a new provision on re-dispensing of medicinal products (Art. 207a), and adjustment of the transposition deadline (Art. 219);
    - in the proposed Regulation, related to the obligation to supply medicinal products and penalties (Art. 5a), the list of critical shortages of Union concern (Art. 122), the list of critical medicinal products (Art. 127), regulatory sandboxes (Chapter IX), as well as adaptations clarifying the scope of the centralised marketing authorisation procedure (Art. 3, Art. 4 and Annex I).

III. CONCLUSION

11. In light of the above, the Permanent Representatives Committee is invited to:
    - examine the overall compromise texts, as set out in documents 8539/25 (for the Directive) and 8537/25 (for the Regulation) and indicate its agreement on it;
    - mandate[9] the Presidency to enter into negotiations with the European Parliament on the basis of this text in view to reach an agreement at first reading on the proposals for a Directive on the Union code relating to medicinal products for human use and a Regulation laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency.

---

[9] In accordance with the approach on legislative transparency endorsed by the Permanent Representatives Committee on 14 July 2020 (doc. 9493/20), and in full consistency with Regulation (EC) No 1049/2001 and the Council's Rules of Procedure, the agreed mandate will be made public.